Olaparib AZD-2281 CAS 763113-22-0 Ịdị ọcha ≥99.0% API Factory
Ịdị ọcha dị elu, mmepụta azụmahịa
Olaparib na ndị etiti emetụtara:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoic acid CAS 763114-26-7
1- (Cyclopropylcarbonyl) piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Aha Chemical | Olaparib |
| Ụdị okwu | AZD-2281;KU0059436;Lynparza;4- (3- (4- (cyclopropanecarbonyl) piperazine-1-carbonyl) -4-fluorobenzyl) phthalazin-1 (2H) -otu;1- (Cyclopropylcarbonyl) -4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl) Methyl]-2-fluorobenzoyl] piperazin |
| Nọmba CAS | 763113-22-0 |
| Nọmba CAT | RF-API103 |
| Ọnọdụ Ahịa | Na Akụrụngwa, Mpụta Ihe ruru narị narị kilograms |
| Usoro ihe omimi | C24H23FN4O3 |
| Ibu molekụla | 434.46 |
| Solubility | Soluble na DMSO |
| Ụdị | Ruifu Chemical |
| Ihe | Nkọwapụta |
| Ọdịdị | Ọcha ka Gbanyụọ-Ọcha ntụ ntụ |
| Nchọpụta nke 1H NMR | Soro usoro |
| LC-MS | Soro usoro |
| Ụzọ ịdị ọcha / nyocha | ≥99.0% (nke LC-MS) |
| Mmiri (KF) | ≤0.50% |
| Otu adịghị ọcha | ≤0.50% |
| Mgbakọta adịghị ọcha | ≤1.0% |
| Ọla dị arọ (dị ka Pb) | ≤20ppm |
| Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
| Ojiji | API;Ihe mgbochi PARP |
ngwugwu: Kalama, Aluminom foil bag, Cardboard Drum, 25kg / Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri.
Olaparib (CAS: 763113-22-0), onye na-eme ihe ike na nhọrọ PARP-inhibitor.Na Disemba 19, 2014, FDA kwadoro ọgwụ mgbochi ọrịa cancer Olaparib (Lynparza) maka monotherapy nye ndị ọrịa nwere ọrịa cancer ovarian dị elu bụ ndị meworo opekata mpe 3 okirikiri chemotherapy ma ọ bụ ndị ọrịa nke mgbanwe mgbanwe BRCA a na-enyo enyo.N'otu oge ahụ, FDA kwadoro ọnụọgụ na nhazi ọkwa nke ngwa nyocha maka nchọpụta mmụgharị na BRCA1 na BRCA2, BRACAnalysis CDx.Olaparib bụ ọgwụ mgbochi mbụ nke PARP nke FDA kwadoro.Na February 2, 2015, European Union Food and Drug Administration (EMA) kwadoro Olaparib ịbanye n'ahịa na mba 28 nke European Union gụnyere Iceland, Liechtenstein na Norway.Ma ihe ngosi nke EMA na FDA kwadoro dịtụ iche;nke mbụ bụ maka mkpụrụ ndụ mkpụrụ ndụ ihe nketa BRCA, yana maka ọgwụgwọ mmezi maka ndị ọrịa nwere ọrịa kansa epithelial ovarian dị elu bụ ndị nataralarị ọgwụ chemotherapy nwere platinum ma gosipụta nzaghachi ma dabere na nlọghachi.
